Altimmune reported that pemvidutide, a GLP-1/glucagon receptor agonist, reduced heavy drinking days in a Phase 2 alcohol use disorder trial versus placebo. The company said the result was statistically significant and accompanied by consistent positive secondary outcomes tied to drinking severity. The trial, called RECLAIM, evaluated pemvidutide dosing against placebo in patients with moderate-to-severe alcohol use disorder, aligning with Altimmune’s strategy of repurposing metabolic pathway biology into addiction and liver-related disease. Altimmune also pointed to planned next steps, including potential pivotal work for fatty liver disease MASH. The readout adds to a growing clinical interest in GLP-1-based mechanisms for behaviors linked to reward and consumption. For drug developers, it also raises competitive considerations around whether next-generation GLP-1 or dual-agonist formulations can meaningfully differentiate in psychiatric and substance-use indications. As the field absorbs signals from the broader GLP-1 platform, RECLAIM’s Phase 2 win becomes a key checkpoint for deciding if pemvidutide’s mechanism can translate into durable clinical benefit.